- The Male Voice: A Qualitative Assessment of Young Men's Communication Preferences About HPV and 9vHPV. [Journal Article]
- JCJ Community Health 2019 May 09
- In the U.S. there is an epidemic of sexually transmitted diseases (STIs). One of the most prevalent STIs is the Human Papillomavirus (HPV). Certain high risk strains of HPV are believed to cause virt…
In the U.S. there is an epidemic of sexually transmitted diseases (STIs). One of the most prevalent STIs is the Human Papillomavirus (HPV). Certain high risk strains of HPV are believed to cause virtually all cervical cancers, over 90% of anal cancers, 70% of oropharyngeal cancers, and the majority of anal genital warts. HPV is preventable through vaccination and is available for both men and women. Several educational interventions have been employed, yet baseline awareness and knowledge related to HPV and 9vHPV remains relatively low among young men. What is not known is the most effective method for providing HPV and 9vHPV information to young men. The purpose of this qualitative study was to learn from young men on how they would like to receive HPV and 9vHPV information. Men between the ages of 18-26 were invited to participate in the study. Ten focus group sessions with a total of 68 participants were conducted from three Midwest community colleges. Analysis resulted in themes related to STIs, HPV and 9vHPV knowledge, 9vHPV receipt, sexual health communication, and communication strategies. Findings suggest that there is not a "one size fits all" preferred communication modality. Recommendations for effective HPV communication include healthcare practitioner self-awareness, community environments where healthcare practitioners can engage in HPV related cancer prevention activities and advocacy for medically accurate sexual health education. Insight into the best way to communicate HPV and 9vHPV information to young men will lead toward improvement in health literacy around HPV, increased 9vHPV uptake, as well as effective health promotion and disease prevention.
- Long intervals between two doses of HPV vaccines and magnitude of the immune response: A post-hoc analysis of two clinical trials. [Journal Article]
- HVHum Vaccin Immunother 2019 Apr 24
- The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6- month or a 3-8 year interval between two HPV vaccine doses. The results from two clinical trials, con…
The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6- month or a 3-8 year interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA methodology were compared. In the first study, 173 9-10 year-old girls and boys received two doses of 9vHPV vaccine at a 6-month interval; in the second study, 31 girls vaccinated with one dose of 4vHPV at the age of 9-14 years received a dose of 9vHPV 3-8 years later (mean 5.4 years). In both studies blood samples were collected before and 1 month post-second dose. Despite large differences in the time since the first dose, all subjects (100%) were seropositive to the common 4 HPV types (6, 11, 16 and 18) to both vaccines, with comparable GMTs and titer distributions before the second dose. One-month post-second dose, the GMTs increased 40- to 91-fold for those with a 6-month interval between doses and 60- to 82-fold for those with a 3-8 year interval. Titer distributions after the booster dose were comparable in the two studies. These results indicate that 2-dose HPV vaccination schedules with an interval of several years could be used for pre-adolescents. Intervals longer than 6 months may facilitate logistics for immunization programs and could be useful during periods of vaccine shortage or as a transition while the effectiveness of a one-dose schedule is being evaluated. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or of the Quebec Public Health Institute.
- Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. [Journal Article]
- GOGynecol Oncol 2019 Apr 11
- CONCLUSIONS: Effective implementation of the 9vHPV vaccine may substantially reduce the burden of HPV-related diseases and related medical procedures.
- Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies. [Journal Article]
- SPSalud Publica Mex 2018 Nov-Dic; 60(6):645-652
- CONCLUSIONS: Implementation of universal HPV vaccination programs, including men, is a public health priority.
- Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. [Journal Article]
- HVHum Vaccin Immunother 2019 Jan 30; :1-13
- Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Span…
Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Spanish vaccination calendar since 2007. The new nonavalent HPV vaccine (9vHPV), approved in Europe in 2015, includes nine HPV types 6/11/16/18/31/33/45/52/58 and has been available in Spain since May 2017. Our study aims to estimate the epidemiological impact and the cost-effectiveness of a girls-only and a gender-neutral vaccination program with 9vHPV compared to the current vaccination program in Spain. A dynamic transmission model simulating the natural history of HPV infections was calibrated to the Spanish setting and applied to estimate costs and quality-adjusted life years (QALYs) associated with vaccination strategies using a payer perspective and a 100-year time horizon. A girls-only vaccination strategy at age 12 years with 9vHPV was found to be a cost-effective strategy compared with 4vHPV (incremental cost-effectiveness ratio (ICER) of €7,718 per QALY). Compared with girls-only vaccination with 4vHPV, gender-neutral vaccination with 9vHPV was associated with further reductions of up to 28.5% in the incidence of cervical intraepithelial neoplasia (CIN) 2/3 and 17.1% in the incidence of cervical cancer, as well as with a 14.0% reduction in cervical cancer mortality. Furthermore, a gender-neutral vaccination program with 9vHPV could potentially be cost-effective considering some parameters as head and neck protection or discount rates, leading to a reduction in the burden of HPV-related diseases in both sexes in the Spanish population.
- Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. [Journal Article]
- VVaccine 2019 Feb 21; 37(9):1229-1234
- CONCLUSIONS: No unexpected AEs were observed among these pregnancy reports.
- The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? [Journal Article]
- ESEuro Surveill 2018; 23(41)
- CONCLUSIONS: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.
- Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. [Randomized Controlled Trial]
- VVaccine 2018 11 12; 36(46):7017-7024
- CONCLUSIONS: The results show the mixed HPV vaccination schedules used in this study are immunogenic and have an acceptable safety profile. Although the seroprotective threshold of antibodies remains unknown the 100% seropositivity to all 9 HPV types included in 9vHPV and the increase of GMTs observed in all study groups post-second dose administration are reassuring and suggest protection might be achieved regardless of the schedule used.
- Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men. [Journal Article]
- FMFuture Microbiol 2018; 13:1463-1472
- CONCLUSIONS: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.
New Search Next
- Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. [Journal Article]
- HVHum Vaccin Immunother 2019; 15(1):141-145
- CONCLUSIONS: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis.